Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes.

摘要

Patients with type 2 diabetes (T2DM) are at substantially higher risk of mortality, primarily from cardiovascular disease, than the general population [1]. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) remains the only large-scale, prospective, secondary prevention trial carried out entirely in patients with T2DM [2]. This trial provides information of a possible macrovascular benefit with pioglitazone (PGZ), peroxisome proliferators-activated receptorgamma (PPAR-gamma) agonists, thiazolidinedione (TZD), particularly in terms of major adverse cardiovascular events, despite only showing a statistical trend towards benefit for the primary composite outcome.